On Friday, September 18, 2026, Shah Rukh, Ajay Devgn and Tiger Shroff were reportedly publicly labelled “violators of law” by Food and Drug Administration (FDA) chief Tukaram Mundhe over promotional advertisements for Vimal. The statement reportedly places three prominent film personalities inside a regulatory controversy involving brand endorsements. The supplied facts identify Mundhe as the FDA commissioner and head of the department, although that designation remains unconfirmed.
Key Details in the Vimal Ad Row
The central fact is the wording used against the actors. Mundhe reportedly described Khan, Devgn and Shroff as “violators of law”, linking the criticism to advertisements promoting Vimal.
The statement was made on September 18, 2026, but the available facts do not establish the specific legal provision, notice, penalty or enforcement action involved. That distinction matters. A public accusation is not the same as a final adjudication, and no verified information supplied for this report confirms that the actors have been fined, prosecuted or formally found guilty by a court or regulator.
| Person | Role in controversy | Verified position |
|---|---|---|
| Shah Rukh Khan | Vimal promotional advertisement | Publicly labelled a “violator of law” |
| Ajay Devgn | Vimal promotional advertisement | Publicly labelled a “violator of law” |
| Tiger Shroff | Vimal promotional advertisement | Publicly labelled a “violator of law” |
| Tukaram Mundhe | FDA chief | Made the public statement |
For Bollywood, the commercial issue is wider than one advertisement. Endorsements convert star visibility into brand value, while regulatory language can shift attention from recall and reach to compliance and public accountability. Coverage of celebrity statements, such as Jyothika Suriya's Says, shows how quickly entertainment news can move beyond film releases when a public figure becomes part of a wider debate.
Shah Rukh, Devgn and Tiger: Why the Label Matters
The three actors do not carry identical market positions, but they share high public recognition. That makes the Vimal controversy commercially significant even without a verified estimate of advertising fees, campaign reach or financial impact. Supporters of celebrity advertising may argue that responsibility for product claims rests primarily with the brand. The counterargument is that a familiar face can make a promotion more persuasive, particularly when audiences associate the actor with credibility or aspiration. For more detail, see Times of India Entertainment.
Mundhe’s wording directly challenges that defence by placing the endorsers themselves at the centre of the alleged legal concern. The available facts do not confirm whether the advertisement involved a direct tobacco product, a surrogate promotion (advertising a related product to bypass restrictions) or another category connected to Vimal. That missing detail prevents a precise assessment of the alleged violation. It also means claims about penalties, bans or future campaigns would be premature. The public reaction may extend beyond this case. Entertainment audiences have previously scrutinised celebrity conduct in controversies unrelated to cinema, as seen in coverage linked to Son Ye Jin's Bold public narrative and Lee Jun Hyuk and the entertainment business. For more detail, see VentureBeat AI.
What Happens Next in the Vimal Ad Row?
The next meaningful development would be an official notice, clarification or order from the FDA. None of those outcomes is confirmed in the supplied facts. Until such a document becomes available, the strongest verified account is limited to Mundhe’s public statement and the actors’ association with Vimal promotional advertising.
The controversy could affect how agencies assess endorsement risk. A campaign featuring major stars may deliver visibility, but legal scrutiny can create reputational costs for the brand, agency and celebrity at the same time. That risk is especially relevant when an advertisement sits near a regulated product category. The actors’ responses, if issued, will determine whether the story becomes a short-lived advertising dispute or a larger debate about celebrity accountability. For now, the regulatory claim remains the headline, while the precise legal basis remains unspecified.
The Vimal ad row shows why Shah Rukh and other stars now face scrutiny not only for what they promote, but also for the regulatory meaning audiences attach to that promotion.
FAQs
What is the Vimal ad row?
The Vimal ad row concerns promotional advertisements for the Vimal brand and public criticism from FDA chief Tukaram Mundhe.
Who were called “violators of law”?
Shah Rukh Khan, Ajay Devgn and Tiger Shroff were publicly described with that phrase by Mundhe.
When were the statements made?
The public statements were made on Friday, September 18, 2026.
Is a penalty confirmed?
No verified fact supplied for this report confirms a fine, prosecution, formal notice or final legal finding. Understanding shah rukh fully means staying ahead of these developments.
Was this article helpful?
Your feedback directly improves future articles on this site.
